HEAD-TO-HEAD CARD DATA MAY
CHANGE HOW YOU
SEE JEVTANA®
(cabazitaxel)
SEE EFFICACY & SAFETY

JEVTANA Was Studied Across 3 Trials in More Than 2200 Men With mCRPC Who Received a Docetaxel-Containing Regimen1

About the CARD Trial

JEVTANA combined with prednisone demonstrated improved efficacy outcomes when compared with a second androgen-signaling-targeted inhibitor (ASTI) (abiraterone or enzalutamide), in mCRPC patients who had previously received a docetaxel-containing regimen.1

  • 2x rPFS
    (median 8.0 months [95% CI: 5.7-9.2] with JEVTANA [n=129] vs 3.7 months [95% CI: 2.8-5.1] with abiraterone or enzalutamide [n=126]; HR=0.54; 95% CI: 0.40-0.73; P<0.0001)1
  • 36% Relative Reduction in Risk of Death
    (median OS, 13.6 months [95% CI: 11.5-17.5] with JEVTANA [n=129] vs 11.0 months [95% CI: 9.2-12.9] with abiraterone or enzalutamide [n=126]; HR=0.64; 95% CI: 0.46-0.89; P=0.008). At the cutoff date, 153 deaths were noted, with 70 (54.3%) in the JEVTANA group and 83 (65.9%) in the abiraterone or enzalutamide group1,2

Study Design

A randomized, open-label, multicenter trial in patients (N=255) with mCRPC who previously received docetaxel and had progressed within 12 months on an androgen-signaling-targeted inhibitor—either abiraterone or enzalutamide. These patients were randomized 1:1 to JEVTANA (n=129) or abiraterone or enzalutamide (n=126); patients received abiraterone if they were previously treated with enzalutamide, or enzalutamide if they were previously treated with abiraterone.1,2

STUDY DESIGN

NCCN

DESIGNATED CATEGORY 1

Cabazitaxel (JEVTANA) is a National Comprehensive Cancer Network® (NCCN®) designated category 1 2nd-line therapy option in mCRPC after docetaxel and a novel hormonal therapy3

mCRPC=metastatic castration-resistant prostate cancer; rPFS=radiographic progression-free survival.



Ready to start a patient on JEVTANA in your practice?


See a detailed overview of treatment with JEVTANA

Hear Dr. Slovin share an example of an mCRPC patient who she is currently treating with JEVTANA.

Susan Slovin, MD, PhD
Medical Oncologist,
Memorial Sloan Kettering Cancer Center


WATCH VIDEO




TROPIC Results

The pivotal trial (N=755) validated JEVTANA as a
treatment in mCRPC after docetaxel.1,4

SEE EFFICACY & SAFETY

PROSELICA Results

This trial (N=1200) established JEVTANA 20 mg/m2 as
the recommended starting dose.1

SEE EFFICACY & SAFETY

Learn about mechanisms of progression

ABOUT mCRPC